The COVID-19 pandemic has shed light on the problem of national drug security and has given a new perspective on growth strategies for the Russian pharma industry. Self-sufficiency and the domestic development of innovations must be placed at the heart of efforts to strengthen Russias pharma industry. Domestic manufacturing of active pharmaceutical ingredients (API) must be built up, and an environment conducive to developing the innovative Russian pharma industry must be created. Facilitating the growth of full-cycle pharmaceutical manufacturing, as well as moving the focus of regulatory policy from building generics portfolios to creating and launching a full range of Russian-developed innovative drugs, may help achieve several goals. It could ensure the countrys drug security, and also help the competitive Russian pharma industry become a leader in global markets. What regulatory decisions and government incentives are needed to create a new competitive API industry? What forms of state support as well as statutory and regulatory innovations will help boost the innovative pharma industry in Russia? What mechanisms need to be developed to commercialize both Russian and foreign medical research and developments? What other steps to boost the national pharma industry could solve the problem of ensuring public availability of a wide range of drugs, planning the product mix, and preventing deficits? Would a protectionist policy provoke a conflict of interests, and would a strategy of offering preferences to Russian manufacturers become a barrier, limiting the market presence of international companies, and reducing the availability of drugs already registered in other markets to patients? Is the Pharma 2030 strategy capable of taking the Russian pharma industry to the international market as a confident and strong player?